Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22587363 | 0.86 | ADRA2A (0.49) | ADRA2AGABRB3GABRA1GABRG2GABRB2 | |
| SCHEMBL3724536 | 0.77 | ADRA2A (0.43) | ADRA2AGABRB3GABRA1GABRG2GABRB2 | |
| SCHEMBL2525541 | 0.77 | ADRA2A (0.47) | ADRA2AGABRB3GABRA1GABRG2GABRB2 | |
| SCHEMBL6854538 | 0.77 | TSHR (0.44) | ADRA2AGABRB3GABRA1GABRG2GABRB2 | |
| SCHEMBL4659933 | 0.75 | KIF11 (0.45) | ADRA2AGABRB3GABRA1GABRG2GABRB2 | |
| SCHEMBL80368 | 0.74 | KIF11 (0.43) | ADRA2AGABRB3GABRA1GABRG2GABRB2 | |
| SCHEMBL2525989 | 0.74 | ADRA2A (0.42) | ADRA2AGABRB3GABRA1GABRG2GABRB2 | |
| SCHEMBL14216811 | 0.73 | HCAR3 (0.35) | HCAR3HCAR2 | |
| SCHEMBL2528314 | 0.73 | GABRA1 (0.41) | ADRA2AGABRB3GABRA1GABRG2GABRB2 | |
| SCHEMBL3727466 | 0.73 | KDM1A (0.53) | ADRA2AGABRB3GABRA1GABRG2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100226938-A1 | Cellular and viral inactivation | HEALTH AND HUMAN SERVICES, GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF | 2010-09-09 | — | — | US | claimed |
| US-20090297558-A1 | Inactivated Influenza Virus Compositions | DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH, GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE | 2009-12-03 | — | — | US | claimed |
| WO-2008054481-A2 | IMPROVED INACTIVATED INFLUENZA VIRUS COMPOSITIONS | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2008-05-08 | — | — | WO | claimed |
| EP-1727894-A1 | CELLULAR AND VIRAL INACTIVATION | Government of the United States of America as represented by The Secretary of the Department of Health and Human Services (US) | 2006-12-06 | — | — | EP | claimed |
| WO-2005093049-A1 | CELLULAR AND VIRAL INACTIVATION | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-10-06 | — | — | WO | claimed |
| US-12629683-B2 | Oligonucleotide encoded chemical libraries | Plexium, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12577702-B2 | Oligonucleotide encoded chemical libraries, related systems, devices, and methods for detecting, analyzing, quantifying, and testing biologics/genetics | Plexium, Inc. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12297461-B2 | Methods of producing and characterizing virus vaccine and virus vaccine composition | GUANGZHOU REALBENEFITSPOT PHARMACEUTICAL CO., LTD. (CN) | 2025-05-13 | — | — | US | disclosed |
| US-12030057-B2 | Oligonucleotide encoded chemical libraries | Plexium, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4382183-A2 | METHODS OF PRODUCING AND CHARACTERIZING VIRUS VACCINE AND VIRUS VACCINE COMPOSITION | Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| EP-3420076-B1 | METHODS OF PRODUCING AND CHARACTERIZING VIRUS VACCINE AND VIRUS VACCINE COMPOSITION | GUANGZHOU REALBENEFITSPOT PHARMACEUTICAL CO LTD (CN) | 2024-02-21 | — | — | EP | disclosed |
| US-20230234065-A1 | OLIGONUCLEOTIDE ENCODED CHEMICAL LIBRARIES | Plexium, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-8268602-B2 | Cellular and viral inactivation | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2417251-A1 | METHOD FOR PURIFYING THE RABIES VIRUS | Sanofi Pasteur (FR) | 2012-02-15 | — | — | EP | disclosed |
| US-20110038890-A1 | Cellular And Viral Inactivation | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2011-02-17 | — | — | US | disclosed |
| WO-2010116096-A1 | METHOD FOR PURIFYING THE RABIES VIRUS | SANOFI PASTEUR (FR) | 2010-10-14 | — | — | WO | disclosed |
| US-20100260798-A1 | Method for purifying the rabies virus | SANOFI PASTEUR (FR) | 2010-10-14 | — | — | US | disclosed |
| US-20100226938-A1 | Cellular and viral inactivation | HEALTH AND HUMAN SERVICES, GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF | 2010-09-09 | — | — | US | disclosed |
| US-20090297558-A1 | Inactivated Influenza Virus Compositions | DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH, GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE | 2009-12-03 | — | — | US | disclosed |
| US-20090297558-A1 | Inactivated Influenza Virus Compositions | DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH, GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629683-B2 | Oligonucleotide encoded chemical libraries | POLL, PCNA, POLM | ADRA2A 4697/4885GABRB3 2039/4885GABRA1 1941/4885 |
| US-20090297558-A1 | Inactivated Influenza Virus Compositions | ITPA, IDO1, IDE | ADRA2A 3648/4885GABRB3 2853/4885GABRA1 2575/4885 |
| US-20100260798-A1 | Method for purifying the rabies virus | NAPA, PBRM1, S100B | ADRA2A 4561/4885GABRB3 40/4885GABRA1 56/4885 |
| US-20110038890-A1 | Cellular And Viral Inactivation | PDIA5, HAVCR2, MAVS | ADRA2A 4723/4885GABRB3 4031/4885GABRA1 3646/4885 |
| US-20100226938-A1 | Cellular and viral inactivation | TP53, IFNG, POLI | ADRA2A 4550/4885GABRB3 3474/4885GABRA1 2983/4885 |
| US-12577702-B2 | Oligonucleotide encoded chemical libraries, related systems, devices, and methods for detecting, analyzing, quantifying, and testing biologics/genetics | RNGTT, TNFSF11, PCNA | ADRA2A 4717/4885GABRB3 3010/4885GABRA1 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.